4 results about "Testosterone deficiency" patented technology

A transdermal testosterone delivery device and methods are disclosed, which improve on the delivery efficiency, therapeutic efficacy, and mitigation of certain risks with respect to 1.62% testosterone gel. The device consists of metalized foil, adhesive membrane, gauze, and paper. The methods include a method of modifying 1.62% testosterone gel to create an ointment which may be administered without material adverse consequence, a method of sizing the device to the magnitude of the applied dose, and a method of timing the application and duration of doses. The device and methods provide therapeutically effective treatment of testosterone deficiency with a better subjective experience of quality of life, while using less testosterone, compared to 1.62% testosterone gel used in isolation according to its labeling.

Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. In some embodiments, the subject has adequately controlled blood pressure.

The present invention relates to the use of ultrasound imaging techniques and computer implemented image processing methods for determining and assessing male infertility, as well as non-invasive diagnostic methods to identify and diagnose male infertility, such as hypogonadism (testosterone deficiency). Furthermore, the invention relates to methods of selecting male subjects for fertility treatment and methods for the treatment of these subjects.

The invention relates to an application of interleukin IL-27 in preparation of a medicine for improving an individual testosterone secretion level, and compared with the prior art, the application has the following advantages that the interleukin IL-27 is taken as an entry point, an IL-27mRNA-LNP therapy is creatively applied to a brand new indication for improving an endogenous testosterone level, and the application has a wide application prospect. The research finds and verifies for the first time that the IL-27 protein with biological activity can be successfully expressed through subcutaneous injection of IL-27mRNA-LNP, and the IL-27 protein acts on the center and the periphery at the same time, so that a brand-new and safer potential treatment scheme is provided for treating testosterone deficiency; the application boundary of biological function cognition of the IL-27 and the mRNA-LNP technology is expanded, and important scientific significance and clinical transformation value are achieved.